Comparison of 3'-deoxy-3'-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma

Nuclear Medicine and Biology

Volumn 39, Issue 7, 2012, Pages 977-981

  Jeong, Su Young ^a   Lim, Sang Moo ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 FLUOROETHYL F 18) LEVO TYROSINE; 3' FLUOROTHYMIDINE F 18; GADOLINIUM PENTETATE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MEDICAL ASSESSMENT; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BRAIN NEOPLASMS; DIDEOXYNUCLEOSIDES; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; TYROSINE;

EID: 84866032360     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.02.009     Document Type: Article

References (30)

1. Burnetti A., Alfano B., Soricelli A., Tedeschi E., Mainolfi C., Covelli E.M., et al. Functional characterization of brain tumours: an overview of the potential clinical value. Nucl Med Biol 1996, 23:699-715.
2. Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005, 64:479-489.
3. Earnest Ft., Kelly P.J., Scheithauer B.W., Kall B.A., Cascino T.L., Ehman R.L., et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 1988, 166:823-827.
4. Johnson P.C., Hunt S.J., Drayer B.P. Human cerebral gliomas: correlation of postmortem MR imaging and neuropathological findings. Radiology 1988, 166:823-827.
5. Bagley L.J., Grossman R.I., Judy K.D., Curtis M., Loevner L.A., Polansky M., et al. Gliomas: correlation of magnetic susceptibility artifact with histologic grade. Radiology 1997, 202:511-516.
6. 11C-methionine in the determination of malignancy of gliomas. J Neurol Sci 2006, 246:85-94.
7. 18F-FDG. J Nucl Med 2005, 46:945-952.
8. 18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007, 25:4714-4721.
9. 18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005, 32:653-659.
10. Saga T., Kawashima H., Araki N., Takahashi J.A., Nakashima Y., Higashi T., et al. Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med 2006, 31:774-780.
11. 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005, 46:1948-1958.
12. Jager P.L., Vaalburg W., Pruim J., de Vries E.G., Langen K.J., Piers D.A. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001, 42:432-445.
13. McConathy J., Goodman M.M. Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography. Cancer Metastasis Rev 2008, 27:555-573.
14. Petrirena G.J., Goldman S., Delattre J.Y. Advances in PET imaging of brain tumors: a referring physician's perspective. Curr Opin Oncol 2011, 23:617-623.
15. 18F]fluorethyl)-L:-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 2005, 32:422-429.
16. 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?. J Nucl Med 2006, 47:393-403.
17. Rasey J.S., Grierson J.R., Wiens L.W., Kolb P.D., Schwwartz J.L. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002, 43:1210-1217.
18. 18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2005, 32:257-263.
19. 18F]Fluroethl)-l-tyrosine (FET): a tracer for differentiation of tumor from inflammation in murine lymph node. Eur J Nucl Med Mol Imaging 2002, 29:1039-1046.
20. 18F-FET uptake in experimental soft tissue infection. Eur J Nucl Med Mol Imaging 2002, 29:648-654.
21. 18F]fluoroethyl)-l-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging 2006, 33:932-939.
22. Lahoutte T., Caveliers V., Camargo S.M., Franca R., Ramadan T., Veljkovic E., et al. SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation. J Nucl Med 2004, 45:1591-1596.
23. 18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004, 31:1464-1470.
24. 18F]fluoroethyl)-l-tyrosine PET in patients with suspicious recurrence of glioma after multimodal treatment: initial results of a retrospective comparative study. Nucl Med Mol Imaging 2010, 44(1):45-54.
25. Popperl G., Kreth F.W., Mehrkens J.H., Herms J., Seelos K., Koch W., et al. FET EPT for the evaluation of untreated gliomas: correlation of FDT uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 2007, 34:193-194.
26. 11C-l-methylmethionine. Neurosurgery 1997, 40:276-288.
27. Ginsberg L.E., Fuller G.N., Hashmi M., Leeds N.E., Schomer D.F. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 1998, 49:436-440.
28. Nakamoto Y., Osman M., Cohade C., Marshall L.T., Links J.M., Kohlmyer S., et al. PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation corrected images. J Nucl Med 2002, 43:1137-1143.
29. 18F-FDG PET images: measured attenuation correction vs. segmented attenuation correction. Nucl Med Mol Imaging 2007, 41:49-53.
30. 137Cs point source. Korean J Nucl Med 2005, 39:57-68.